Wnt/β-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-κb activation in cancer cells

Cancer Research

Volumn 69, Issue 9, 2009, Pages 3764-3771

  Du, Qiang ^a   Zhang, Xinglu ^a   Cardinal, Jon ^a   Cao, Zongxian ^a   Guo, Zhong ^a   Shao, Lifang ^a   Geller, David A ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; WNT PROTEIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL ACTIVATION; CELL ACTIVITY; CELL STRAIN HCT116; CELL STRAIN HEPG2; CELL TRANSFORMATION; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO CULTURE; INHIBITION KINETICS; LIVER CANCER; LIVER CELL CARCINOMA; MUTANT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTIGENS, CD95; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CYTOKINES; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; HUMANS; NEOPLASMS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; WNT PROTEINS;

EID: 65949106610     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0014     Document Type: Article

References (50)

1. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32.
2. Morin PJ, Sparks AB, Korinek V, et al. Activation of β- catenin-Tcf signaling in colon cancer by mutations in β- catenin or APC. Science 1997; 275: 1787-90.
3. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-7.
4. Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med 2006; 354: 761-3.
5. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118: 671-4.
6. van de WM, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-50.
7. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 9265-9.
8. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis:mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 1985; 82: 7738-42.
9. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-16.
10. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008; 19: 65-7.
11. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003; 34: 955-68.
12. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-85.
13. Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254: 1001-3.
14. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995; 92: 4392-6.
15. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993; 341: 465-6.
16. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene up-regulation. J Clin Invest 1998; 101: 1343-52.
17. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997; 11: 443-8.
18. Ambs S, Merriam WG, Ogunfusika MO, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4: 1371-6.
19. Forrester K, Ambs S, Lupold SE, et al. Nitric oxideinduced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A 1996; 93: 2442-7.
20. Ambs S, Ogunfusika MO, Merriam WG, et al. Upregulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A 1998; 95: 8823-8.
21. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898-902.
22. Lancaster JR, Jr., Xie K. Tumors face NO problems? Cancer Res 2006; 66: 6459-62.
23. Lowenstein CJ, Alley EW, Raval P, et al. Macrophage nitric oxide synthase gene:two upstream regions mediate induction by interferon g and lipopolysaccharide. Proc Natl Acad Sci U S A 1993; 90: 9730-4.
24. de Vera ME, Shapiro RA, Nussler AK, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines:initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A 1996; 93: 1054-9.
25. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NF-κB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998; 273: 15148-56.
26. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB. Proc Natl Acad Sci U S A 2001; 98: 8638-43.
27. Feng X, Guo Z, Nourbakhsh M, et al. Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter:The role of NF- κB-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci U S A 2002; 99: 14212-7.
28. Karin M. NF-κB and cancer:mechanisms and targets. Mol Carcinog 2006; 45: 355-61.
29. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-6.
30. Du Q, Park KS, Guo Z, et al. Regulation of human nitric oxide synthase 2 expression by Wnt β-catenin signaling. Cancer Res 2006; 66: 7024-31.
31. Deng J, Miller SA, Wang HY, et al. β-Catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell 2002; 2: 323-34.
32. Kim JS, Crooks H, Dracheva T, et al. Oncogenic β- catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002; 62: 2744-8.
33. Ganster RW, Guo Z, Shao L, Geller DA. Differential effects of TNF-αand IFN-γon gene transcription mediated by NF-κB-Stat1 interactions. J Interferon Cytokine Res 2005; 25: 707-19.
34. Geller DA, de Vera ME, Russell DA, et al. A central role for IL-1βin the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1βinduces hepatic nitric oxide synthesis. J Immunol 1995; 155: 4890-8.
35. Kolodziejski PJ, Rashid MB, Eissa NT. Intracellular formation of "undisruptable" dimers of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 2003; 100: 14263-8.
36. Wang H, MacNaughton WK. Overexpressed β-catenin blocks nitric oxide-induced apoptosis in colonic cancer cells. Cancer Res 2005; 65: 8604-7.
37. Sun J, Hobert ME, Duan Y, et al. Crosstalk between NF-κB and β-catenin pathways in bacterial-colonized intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2005; 289: G129-137.
38. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
39. Geller DA, Nussler AK, Di SM, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A 1993; 90: 522-6.
40. Kitade H, Sakitani K, Inoue K, et al. Interleukin 1βmarkedly stimulates nitric oxide formation in the absence of other cytokines or lipopolysaccharide in primary cultured rat hepatocytes but not in Kupffer cells. Hepatology 1996; 23: 797-802.
41. Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001; 1: 1421-41.
42. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994; 79: 1137-46.
43. Lu T, Sathe SS, Swiatkowski SM, Hampole CV, Stark GR. Secretion of cytokines and growth factors as a general cause of constitutive NFκB activation in cancer. Oncogene 2004; 23: 2138-45.
44. Bandino A, Compagnone A, Bravoco V, et al. β- Catenin triggers nuclear factor κB-dependent upregulation of hepatocyte inducible nitric oxide synthase. Int J Biochem Cell Biol 2008; 40: 1861-71.
45. Deng J, Xia W, Miller SA, et al. Crossregulation of NF- κB by the APC/GSK-3β/β-catenin pathway. Mol Carcinog 2004; 39: 139-46.
46. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κ B antiapoptosis:induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase- 8 activation. Science 1998; 281: 1680-3.
47. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-2.
48. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
49. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63: 728-34.
50. Mei JM, Borchert GL, Donald SP, Phang JM. Matrix met alloproteinase (s) mediate (s) NO-induced dissociation of β-catenin from membrane bound E-cadherin and formation of nuclear β-catenin/LEF-1 complex. Carcinogenesis 2002; 23: 2119-22.